NCT02122861: Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 |
|
|
| Completed | 1 | 47 | US | ID-LV305 | Immune Design, Merck Sharp & Dohme LLC | Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed, Sarcoma - Enrollment Completed | 11/18 | 12/18 | | |
